Pantoprazole is a medication prescribed to treat: erosive esophagitis associated with GERD (gastroesophageal reflux disease); gastric acid hypersecretory conditions like Zollinger-Ellison syndrome; and gastric ulceration induced by Helicobacter pylori infection. The medication was originally synthesized in 1985 and received FDA approval in 2000 throughout the United States under the brand name “Protonix.” Research indicates that, …
Lamictal (Lamotrigine) is a medication that was first approved by the FDA in 1994 for the treatment of partial seizures, later in 1998 for the treatment of Lennox-Gastaut syndrome, and again 2003 for the management of bipolar disorder. Specifically, Lamictal is used to prevent and/or treat: focal seizures, tonic-clonic seizures, and acute depressive episodes or …
Lamictal (lamotrigine) is an anticonvulsant medication prescribed for the prophylaxis and/or management of epilepsy and bipolar disorder. Research suggests that Lamictal modifies neurochemistry by: inhibiting voltage-gated sodium channels, blocking various calcium channels (L-type; N-type; P-type), antagonizing sigma and 5-HT3 receptors, upregulating GABA signaling, and suppressing the release of glutamate and aspartate. Through the aforementioned mechanisms …
Lithium is a naturally occurring element that’s commonly prescribed in the format of “lithium carbonate” for the prophylaxis and/or management of bipolar disorder. Additionally, lithium is sometimes prescribed as an adjunct to treat refractory cases of major depressive disorder and schizophrenia. Throughout treatment, lithium is understood to modulate numerous aspects of a user’s neurophysiology to …
Vraylar (Cariprazine), is an atypical antipsychotic medication approved in 2015 by the FDA for the treatment of schizophrenia and bipolar disorder. Occasionally, Vraylar is also prescribed as an adjunct for treatment-resistant depression and off-label for anxiety disorders. Although Vraylar is marketed as an improvement over older atypical antipsychotic medications in terms of efficacy and tolerability, …
Vraylar (Cariprazine), also sold under the name Reagila [in European countries], is an atypical antipsychotic developed by the pharmaceutical company Allergan. In 2015, Vraylar received FDA approval for the treatment of schizophrenia and mania associated with bipolar disorder. From a pharmacodynamic perspective, Vraylar functions predominantly as a partial agonist at D3 and D2 dopamine receptors, …
CBD (Cannabidiol) is a phytocannabinoid with medicinal properties derived from the cannabis plant (i.e. marijuana). Of all ~113 active phytocannabinoids, or plant-based chemical constituents within the cannabis plant, cannabidiol is most abundant and accounts for approximately 40% of the plant’s extract. Unlike other phytocannabinoids that induce intoxicating effects (e.g. THC or tetrahydrocannabinol), cannabidiol is devoid …